1575596-29-0

Usage

Molecular structure

Contains a piperidine ring, a pyrazolo-pyrimidine ring, an oxetane ring, a nitrile group, and an enenitrile group

Functional groups

Piperidine ring, pyrazolo-pyrimidine ring, oxetane ring, nitrile group, enenitrile group

Potential applications

May have pharmaceutical or biochemical applications, but further study and analysis are needed to fully understand its properties and potential uses

Upstream product

• 1414356-84-5 3-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-3-oxopropanenitrile 
• 1575591-71-7 2-methyl-2-[4-(oxetan-3-yl)piperazin-1-yl]propanal 
• 1276110-38-3 (R)-3-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 2380-63-4 4-Aminopyrazolo<3,4-d>pyrimidin 
• 151266-23-8 4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 
• 1414356-82-3 3-(2-fluoro-4-phenoxyphenyl)-1-[(3R)-piperidin-3-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1414356-80-1 tert-butyl (3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate 
• 98-80-6 phenylboronic acid 
• 121219-03-2 4-bromo-3-fluorophenol 
• 1138557-58-0 1-bromo-2-fluoro-4-phenoxybenzene 
• 1414356-30-1 (2-fluoro-4-phenoxyphenyl)-boronic acid 

Relevant academic research and scientific papers

SOLID FORMS OF 2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE

Solid forms of Compound (I): are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions mediated by BTK activity using the same, and methods for making Compound (I) and solid forms thereof are also disclosed.

SALTS AND SOLID FORM OF A BTK INHIBITOR

Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) a

PYRAZOLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS

The present disclosure provides compounds of Formula (LA) and/ or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of ty r-osine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and/or pharmaceutically acceptable salts thereof and processes for preparing such compounds and p h ar-maceutically acceptable salts thereof